In a man with high‑risk prostate cancer (PSA 123 ng/mL) and no distant metastases on staging, is bilateral orchidectomy plus definitive external‑beam radiotherapy (~78 Gy) an appropriate curative treatment?

Bilateral Orchidectomy Plus External Beam Radiation for High-Risk Localized Prostate Cancer

Yes, bilateral orchidectomy combined with definitive external beam radiotherapy (78 Gy) is an appropriate and effective curative treatment for this patient with high-risk, non-metastatic prostate cancer (PSA 123 ng/mL). This approach combines the proven survival benefit of androgen deprivation with definitive local therapy for disease control.

Rationale for Combined Treatment

Patients receiving external beam radiotherapy should receive androgen suppression before, during and after radiotherapy for a minimum of 6 months duration, with 2-3 years recommended for high-risk disease. 1 Bilateral orchidectomy achieves this androgen suppression equivalently to LHRH agonists and is explicitly endorsed as first-line ADT. 1, 2

Evidence Supporting Combined Approach

• A prospective randomized trial demonstrated that combined orchiectomy plus radiotherapy versus radiotherapy alone significantly improved progression-free survival (31% vs 61% progression, p=0.005) and overall survival (38% vs 61% mortality, p=0.02) at median 9.3-year follow-up. 3 This survival benefit was particularly pronounced in node-positive patients.

• External beam radiotherapy doses of 75-80 Gy are now standard for high-risk disease, as dose escalation trials showed superior freedom from biochemical or clinical failure (78% vs 59%, p=0.004) compared to conventional 70 Gy. 1

• The combination of radiotherapy plus neoadjuvant/adjuvant hormonal therapy for 2-3 years improves prostate cancer-specific survival (HR 0.56; 95% CI 0.32-0.98) compared to radiotherapy alone in high-risk disease. 4

Advantages of Bilateral Orchidectomy in This Context

• Rapid testosterone suppression to castrate levels (≤10 ng/mL) occurs within days, providing swift disease control. 2 This is particularly important given the markedly elevated PSA of 123 ng/mL.

• Guaranteed compliance eliminates the risk of missed LHRH injections over the required 2-3 year treatment duration. 2

• Cost-effectiveness is superior for long-term ADT compared to continuous LHRH agonist injections. 2

• Bilateral orchidectomy achieves lower castrate testosterone levels than medical castration, which may translate to better disease control. 5

Radiation Therapy Specifications

• Deliver 75-80 Gy to the prostate using conformal techniques (3D-CRT or IMRT) with daily image-guided radiation therapy (IGRT) for doses >75 Gy. 1

• Include pelvic lymph node irradiation for this high-risk patient, as pelvic imaging should be performed when risk of nodal involvement exceeds 15%. 1 With PSA >100 ng/mL, nodal risk is substantial.

• Treatment planning should use daily prostate localization via implanted fiducials, ultrasound, or electromagnetic tracking to ensure target accuracy and margin reduction. 1

Treatment Timeline

1. Perform bilateral orchidectomy immediately to initiate rapid androgen suppression. 2

2. Begin external beam radiotherapy within 2-3 months to allow neoadjuvant hormonal effect on tumor volume. 1, 4

3. Continue androgen suppression for 2-3 years total (or 4-6 months minimum if only a single high-risk factor, though PSA 123 ng/mL warrants longer duration). 1

4. Monitor testosterone every 3-4 weeks initially to confirm castrate levels <20 ng/dL, then periodically. 2

Critical Pitfalls to Avoid

• Never discontinue castration even if disease progresses to castration-resistant status—continued androgen suppression remains essential for efficacy of subsequent therapies. 1, 2

• Do not use radiation doses <75 Gy for high-risk disease, as conventional 70 Gy is no longer considered adequate. 1

• Avoid omitting pelvic lymph node irradiation in this high-risk patient, as the combination of orchiectomy plus radiotherapy showed particular benefit in node-positive disease. 3

• Do not delay systemic intensification if metastatic disease is later discovered—consider adding docetaxel, abiraterone, enzalutamide, or apalutamide per contemporary standards. 2, 4

Long-Term Monitoring

• Measure PSA with a sensitive assay every 3-6 months to detect biochemical failure early. 1

• Screen for metabolic complications including osteoporosis, diabetes, hypercholesterolemia, and cardiovascular disease, as all forms of castration increase these risks. 2, 4

• Provide bone protection if bone metastases develop, though anti-resorptive agents have limited benefit in non-castrate disease. 2